Hangzhou Jiuyuan Gene Engineering (HKG:2566) said Chinese regulators approved the marketing application of its weight-loss drug Jikeqin, according to a Hong Kong bourse filing Wednesday.
Shares of the firm were up 2% in morning trade Thursday.
The product is a biosimilar version of Novo Nordisk's semaglutide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments